article thumbnail

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

H1 Blog

We’re curious to see what will happen over the next 12 months and how pharma companies will respond.” Find out more by requesting a demo today. “Now, we’re at a place where the rubber is going to meet the road with the FDA reviewers, and we’ll see if they’re going to enforce this new guidance.

FDA 59
article thumbnail

A Lesson in History: Assessing Trial Performance Data for Future Trial Design

H1 Blog

Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. To learn more about how to leverage performance data in your trial planning, request a demo of H1’s Clinical Trial Intelligence solution – Trial Landscape.

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Four Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in Medicine

H1 Blog

For example, platforms like H1’s allow pharma professionals to find experienced professionals willing to engage in meaningful dialogue about relevant topics related to their field of expertise.

article thumbnail

Why Drug Approvals and Development Hinge on Diversity

H1 Blog

To learn more about how H1 can help diversify your HCP engagement strategy, request a demo.

article thumbnail

Three Ways Field Medical Teams Can Close Care Gaps and Increase Scientific Share of Voice

H1 Blog

In some of our work with leading global pharma companies, we have been in a unique position to notice patterns in the ways organizations struggle or simply fail to engage and support external experts. Please request a demo to learn how HCP Universe can help you achieve ruthless preparedness as a medical affairs professional.

Science 52